Wasatch Micro Cap: “Pennant (PNTG) Will Show Improvement in the Coming Quarters”
Wasatch Global Investors, an investment management firm, published its “Wasatch Micro Cap Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 10.95% was recorded by the fund for the Q1 of 2021, trailing the benchmark, Russell Microcap Index, which rose 23.89% for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Wasatch Micro Cap, in its Q1 2021 investor letter, mentioned The Pennant Group, Inc. (NASDAQ: PNTG), and shared their insights on the company. The Pennant Group, Inc. is an Idaho, United States-based home health care services company that currently has a $1.09 billion market capitalization. Since the beginning of the year, PNTG delivered a -35.11% return, while its 12-month gains are up by 115.78%. As of May 07, 2021, the stock closed at $38.38 per share.
Is Danimer Scientific Inc. (DNMR) A Smart Long-Term Buy?
Nelson Capital Management, an investment management firm, published its first-quarter 2021 investor letter – a copy of which can be downloaded here. In the letter, the fund discussed their interpretation of the economy’s reopening drives, their asset transactions, tax updates, featured equity, and a special topic about the life after the pandemic. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Nelson Capital Management, in its Q1 2021 investor letter, mentioned (NYSE: DNMR), and shared their insights on the company. Danimer Scientific, Inc. is a Georgia, United States-based biopolymer manufacturer that currently has a $1.5 billion market capitalization. Since the beginning of the year, DNMR delivered a -69.16% return, while its 12-month gains are down by -25.78%. As of May 07, 2021, the stock closed at $17.45 per share.
Quarterly Results
Earnings per share were up 131.58% year over year to $0.44, which beat the estimate of $0.39.
Revenue of $152,828,000 rose by 170.25% year over year, which beat the estimate of $151,640,000.
Outlook
Revenue guidance hasn t been issued by the company for now.
How To Listen To The Conference Call
Date: May 10, 2021
Quarterly Results
Earnings per share were up 144.00% year over year to $0.61, which beat the estimate of $0.50.
Revenue of $287,000,000 rose by 30.32% year over year, which beat the estimate of $272,280,000.
Guidance
Q3 revenue expected to be between $300,000,000 and $320,000,000.
How To Listen To The Conference Call
Date: May 10, 2021
Price action over last quarter: down 12.34%
Company Description
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington s disease and cognitive impairment; and addictive and compulsive disorders.